Tacrolimus Topical and Estradiol Interaction

Understanding the Tacrolimus Topical and Estradiol Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Tacrolimus Topical belongs to the Calcineurin Inhibitor (Topical) class and Estradiol belongs to the Estrogen Hormone class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Estradiol can slow down how your body breaks down tacrolimus, which may increase the amount of medicine in your blood to unsafe levels. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Tacrolimus Topical has 25 total documented interactions on file in this dataset, and Estradiol has 54. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your healthcare provider should check your blood levels and watch for any signs of toxicity while you are using both medications. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Tacrolimus Topical or Estradiol based on a web page, speak with your prescriber or pharmacist before making any change.